Supplementary materials: Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China

<b>These are peer-reviewed supplementary materials for the article '</b><b>Cost–effectiveness analysis of </b><b>prolonged-release fampridine to treat </b><b>walking disability of multiple sclerosis in </b><b>China</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Symptomatic medications and duration of treatment in multiple sclerosis (MS) adult patients with walking disability (EDSS [expanded disability status scale] score 4-7)</b><b>Frequency and duration of rehabilitation therapy in MS adult patients with walking disability (EDSS score 4-7)</b><b>Healthcare resource utilization in the treatment of MS adult patients with walking disability (EDSS score 4-7)</b><b>The relationship between walking ability and costs</b><b>Supplementary Table 1 EQ-5D-5L utilities from the ENHANCE and MOBILE trial</b><b>Objectives: </b>This study evaluates the cost–effectiveness of adding prolonged-release (PR)-fampridine to best supportive care (BSC) versus BSC alone in adult multiple sclerosis patients with walking disability in China. <b>Materials &amp; methods:</b> A hybrid decision tree and Markov model from both the societal and healthcare perspectives were constructed. Parameters were derived from clinical trials of PR-fampridine, published sources and clinical expert interviews. <b>Results: </b>Over a 10-year time horizon, adding PRfampridine to BSC led to 0.15 quality-adjusted life year (QALY) gain and lower costs,with incremental cost–effectiveness ratios of -238,806 Chinese Yuan/QALY and -113,488 Chinese Yuan/QALY from the societal and healthcare perspectives, respectively. <b>Conclusion:</b> Compared with BSC alone, PR-fampridine plus BSC is considered an economically dominant strategy for the treatment of multiple sclerosis-related walking disability in China.